Potential conflict of interest: Nothing to report.
Hepatic histological findings in suspected drug-induced liver injury: Systematic evaluation and clinical associations
Article first published online: 18 DEC 2013
Copyright © 2013 The Authors. HEPATOLOGY published by Wiley on behalf of the American Association for the Study of Liver Diseases.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Volume 59, Issue 2, pages 661–670, February 2014
How to Cite
Kleiner, D. E., Chalasani, N. P., Lee, W. M., Fontana, R. J., Bonkovsky, H. L., Watkins, P. B., Hayashi, P. H., Davern, T. J., Navarro, V., Reddy, R., Talwalkar, J. A., Stolz, A., Gu, J., Barnhart, H., Hoofnagle, J. H. and for the Drug-Induced Liver Injury Network (DILIN) (2014), Hepatic histological findings in suspected drug-induced liver injury: Systematic evaluation and clinical associations. Hepatology, 59: 661–670. doi: 10.1002/hep.26709
The DILIN network is structured as an U01 cooperative agreement supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institutes of Health (NIH) with funds provided by the following grants: U01DK065193 (University of Connecticut); U01DK065211 (University of Indiana [Purdue]); U01DK065238 (University of California San Francisco/CPMC); U01DK065184 (University of Michigan [Ann Arbor]); U01DK065201 (University of North Carolina Chapel Hill, Asheville, Carolinas Medical Center, Duke); U01DK83023 (University of Texas-Southwestern); U01DK083020 (University of Southern California, UCLA Pfleger Liver Institute); U01DK08992 (Mayo Clinic); U01DK083027 (Thomas Jefferson and University of Pennsylvania); and U01DK065176 (Duke Clinical Research Institute as Data Coordinating Center). This work was supported, in part, by the Intramural Program of the National Cancer Institute, National Institutes of Health. This study is DILIN publication no. 23.
- Issue published online: 29 JAN 2014
- Article first published online: 18 DEC 2013
- Accepted manuscript online: 28 AUG 2013 10:46AM EST
- Manuscript Accepted: 22 AUG 2013
- Manuscript Revised: 16 JUL 2013
- Manuscript Received: 8 MAR 2013
This article has been cited by:
- 1Clinical and Histologic Features of Azithromycin-Induced Liver Injury, Clinical Gastroenterology and Hepatology, 2015, 13, 2, 369, , , , , , , , ,
- 4Protective effect of Th22 cells and intrahepatic IL-22 in drug induced hepatocellular injury, Journal of Hepatology, 2015,, , , , , , , , , , ,
- 5ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury, The American Journal of Gastroenterology, 2014, 109, 7, 950, , , , , ,
- You have free access to this content6
- 7Drug-Induced Liver Injury, Dosage, and Drug Disposition: Is Idiosyncrasy Really Unpredictable?, Clinical Gastroenterology and Hepatology, 2014, 12, 9, 1556,
- 8Drug-induced liver injury: what was new in 2013?, Expert Opinion on Drug Metabolism & Toxicology, 2014, 10, 7, 959, , , ,
- 9Emperipolesis Mediated by CD8 T Cells Is a Characteristic Histopathologic Feature of Autoimmune Hepatitis, Clinical Reviews in Allergy & Immunology, 2014,, , , , , , , , , , , ,
- 10Evolution of the Food and Drug Administration Approach to Liver Safety Assessment for New Drugs: Current Status and Challenges, Drug Safety, 2014, 37, S1, 9,
- 11Glatiramer acetate-induced hepatitis in a young female patient with multiple sclerosis, Multiple Sclerosis and Related Disorders, 2014, 3, 6, 732, , , , , , ,
- You have free access to this content12
- 13Mechanisms of drug-induced liver injury, Current Opinion in Allergy and Clinical Immunology, 2014, 14, 4, 286, , ,
- 14Pathogenesis of Idiosyncratic Drug-Induced Liver Injury and Clinical Perspectives, Gastroenterology, 2014, 146, 4, 914,